Bicara Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
BCAX$10.18+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited, in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(47,038) | $(39,545) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Change in fair value of Series B preferred stock tranche rights liability | — | 13,356 |
| Stock-based compensation | 4,216 | 1,134 |
| Depreciation | 41 | 5 |
| Non-cash lease expense | 199 | 26 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (280) | (855) |
| Accounts payable and accrued expenses | 728 | (410) |
| Accounts payable and accrued expenses – related party | (2,374) | (11,296) |
| Operating lease liabilities | (211) | (7) |
| Net cash used in operating activities | (44,719) | (37,592) |
| Investing activities: | ||
| Purchase of property and equipment | (31) | (150) |
| Proceeds from sale of property and equipment | 62 | — |
| Net cash provided by (used in) investing activities | 31 | (150) |
| Financing activities: | ||
| Proceeds from issuance on common stock, net of issuance costs | 333,479 | — |
| Proceeds from issuance of preferred stock and preferred stock tranche rights, net | — | 77,645 |
| Proceeds from exercise of options | 1,527 | 149 |
| Net cash provided by financing activities | 335,006 | 77,794 |
| Net increase in cash and cash equivalents | 290,318 | 40,052 |
| Cash and cash equivalents at beginning of period | 230,440 | 4,158 |
| Cash and cash equivalents at end of period | $520,758 | $44,210 |
| Supplemental disclosure of cash flow information: | ||
| Non-cash investing and financing activities: | ||
| Settlement of Series B preferred stock tranche rights, upon issuance of milestone shares | $— | $8,001 |
| Right-of-use asset obtained in exchange for lease liability | $— | $703 |
| Vesting of early exercise stock options | $51 | $51 |
| Offering costs included in accounts payable and accrued expenses | $1,052 | $— |
| Series B preferred stock tranche rights liability, upon initial issuance of shares | $— | $642 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.